(NASDAQ: KPTI) Karyopharm Therapeutics's forecast annual revenue growth rate of 13.85% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.6%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.06%.
Karyopharm Therapeutics's revenue in 2026 is $146,067,000.On average, 9 Wall Street analysts forecast KPTI's revenue for 2026 to be $2,572,558,072, with the lowest KPTI revenue forecast at $2,337,021,523, and the highest KPTI revenue forecast at $3,039,228,618. On average, 8 Wall Street analysts forecast KPTI's revenue for 2027 to be $3,147,824,909, with the lowest KPTI revenue forecast at $2,606,677,853, and the highest KPTI revenue forecast at $3,643,112,045.
In 2028, KPTI is forecast to generate $4,016,411,794 in revenue, with the lowest revenue forecast at $2,414,249,628 and the highest revenue forecast at $5,105,860,053.